The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Current treatment landscape for neuroendocrine tumors
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the current treatment landscape for neuroendocrine tumors at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. The prognosis for neuroendocrine tumors is not very positive as physicians have been unsuccessful in developing specific targeted therapies. Dr Kerr explains how more investigation is required, especially for treatments that involve biomarker testing.
